S215: KEYNOTE-667: OPEN-LABEL, PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT-LINE CHEMOTHERAPY

• Luciana Vinti,
• Stephen Daw,
• Constantino Sabado Alvarez,
• Franca Fagioli,
• Auke Beishuizen,
• Gerard Michel,
• Maria Luisa Moleti,
• Michaela Cepelova,
• Anne Thorwarth,
• Charlotte Rigaud,
• Diego Plaza Lopez de Sabando,
• Judith Landman-Parker,
• Juan Shen,
• Pallavi Pillai,
• Patricia Marinello,
• Christine Mauz-Koerholz

Affiliations

Luciana Vinti

1 IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy

Stephen Daw

2 University College London Hospitals NHS Foundation Trust, London, United Kingdom

Constantino Sabado Alvarez

3 Hospital Universitari Vall d Hebron, Barcelona, Spain

Franca Fagioli

4 Regina Margherita Childrens Hospital and University of Turin, Turin, Italy

Auke Beishuizen

5 Princess Máxima Centrum, Utrecht, The Netherlands

Gerard Michel

6 CHU de Marseille Hopital de la Timone Enfants, Marseille, France

Maria Luisa Moleti

7 Universita degli Studi di Roma La Sapienza, Rome, Italy

Michaela Cepelova

8 University Hospital Motol, Prague, Czech Republic

Anne Thorwarth

9 Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum, Berlin, Germany

Charlotte Rigaud

10 Gustave Roussy Cancer Campus, Villejuif, France

Diego Plaza Lopez de Sabando

11 Hospital Universitario La Paz, Madrid, Spain

Judith Landman-Parker

12 Hopital d’Enfants Armand Trousseau, Sorbonne University, Paris, France

Juan Shen

13 Merck & Co., Inc., Rahway, United States

Pallavi Pillai

13 Merck & Co., Inc., Rahway, United States

Patricia Marinello

13 Merck & Co., Inc., Rahway, United States

Christine Mauz-Koerholz

14 Justus-Liebig University of Giessen, Giessen, Germany, and Medical Faculty of the Martin-Luther-University of Halle-Wittenberg, Halle, Germany